Featured Research Search Results

Treating Advanced MSI-High or dMMR Cancers Using the Targeted Therapy MOMA-341 Given Alone or In Combination with Standard Therapies

Clinicaltrials.gov identifier:
NCT06974110

Treatment
Treatment study for people with advanced or metastatic cancers

Study of a New Drug, E7386, in Combination with Lenvatinib in People with Previously Treated Endometrial Cancer

Clinicaltrials.gov identifier:
NCT04008797

Treatment
Treatment study for people with previously treated endometrial cancer

NePtune: Using PARP Inhibitors Before Surgery in Localized Prostate Cancer

Clinicaltrials.gov identifier:
NCT05498272

Treatment
Treatment study for people with intermediate- or high-risk prostate cancer with certain tumor mutations

Treating Advanced Cancers with DNA-Repair Mutations Using MOMA-313 Alone or In Combination with the PARP Inhibitor Olaparib

Clinicaltrials.gov identifier:
NCT06545942

Treatment
Treatment study for people with advanced or metastatic cancers

Pfizer Clinical Trials for Metastatic Prostate Cancer are Now Enrolling

Treatment
Men aged 18 years or older with metastatic prostate cancer

Study of a New Investigational Inhibitor to Treat People with Advanced Solid Tumors

Clinicaltrials.gov identifier:
NCT05932862

Treatment
Treatment study for people with advanced solid tumors

Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer

Clinicaltrials.gov identifier:
NCT06958328

Treatment
Radiation treatment study for people with locally advanced pancreatic cancer

Studying a New PARP Inhibitor and Hormonal Therapy to Treat HER2-negative, HR-positive Metastatic Breast Cancer with a BRCA1, BRCA2, or PALB2 Mutation (EvoPAR BR01)

Clinicaltrials.gov identifier:
NCT06380751

Treatment
Treatment study for HER2-negative, HR-positive metastatic breast cancer with a BRCA1, BRCA2 or PALB2 mutation

Treating Advanced or Metastatic Cancers with a New PARP Inhibitor (GS-0201) Alone or Combined with Other Drugs

Clinicaltrials.gov identifier:
NCT06167317

Treatment
Treatment study for people with advanced or metastatic solid tumors

Treating HER2-negative, Metastatic Breast Cancer with a BRCA or PALB2 Mutation Using a New Drug Combined with Olaparib

Clinicaltrials.gov identifier:
NCT06488378

Treatment
Treatment study for HER2-negative, metastatic breast cancer with a BRCA1/2 or PALB2 mutation

Looking at Tumor DNA Before Chemotherapy to Predict Cancer Recurrence in People with High-Risk, Early-Stage Breast Cancer

Clinicaltrials.gov identifier:
NCT06401421

Treatment
Biomarker study for people with early-stage breast cancer

Testing a Shorter Course of Chemo- and Immunotherapy for People With Early-Stage Triple-Negative Breast Cancer

Clinicaltrials.gov identifier:
NCT05929768

Treatment
Treatment study for early-stage triple-negative breast cancer

Study of the Drug Olvi-Vec in Women with Ovarian Cancer

Clinicaltrials.gov identifier:
NCT05281471

Treatment
Treatment for women diagnosed with platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer or whose cancer did not respond to prior chemotherapy

Olaparib with Cediranib or Ceralasertib for People with Advanced or Metastatic Breast Cancer and with a BRCA1 or BRCA2 Mutation

Clinicaltrials.gov identifier:
NCT04090567

Treatment
Treatment study for people with advanced breast cancer who have a BRCA1 or BRCA2 genetic mutation and who were previously treated with a PARP inhibitor

Studying the Effectiveness of New PARP Inhibitor, Saruparib Compared to Current Treatment Options for Metastatic Prostate Cancer EvoPAR-PRO1

Clinicaltrials.gov identifier:
NCT06120491

Treatment
Treatment study for metastatic, castration-sensitive prostate cancer

Treating Metastatic BRCA1, BRCA2 or PALB2 Pancreatic Cancer Using a New Combination of Chemotherapy Drugs

Clinicaltrials.gov identifier:
NCT06115499

Treatment
Treatment study for people with metastatic pancreatic cancer and a BRCA1, BRCA2 or PALB2 mutation

Treating Metastatic Prostate Cancer with a New PARP Inhibitor AZD5305 Combined With Hormone Therapy

Clinicaltrials.gov identifier:
NCT05367440

Treatment
Treatment study for metastatic prostate cancer

Effectiveness of Lymph Node Mapping to Reduce the Risk of Swelling in the Legs in Patients with Stage I Endometrial Cancer

Clinicaltrials.gov identifier:
NCT05646316

Treatment
People with stage I endometrial cancer who are having a hysterectomy